Key Developments: Synergy Pharmaceuticals Inc (SGYP.O)

SGYP.O on Nasdaq

3:17pm EDT
Price Change (% chg)

$0.02 (+0.52%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Synergy Pharmaceuticals Inc Begins Phase IIb Trial Of Plecanatide In Irritable Bowel Syndrome With Constipation
Thursday, 27 Dec 2012 05:00am EST 

Synergy Pharmaceuticals Inc announced that dosing has commenced in a Phase IIb clinical trial of plecanatide to treat patients with constipation-predominant irritable bowel syndrome (IBS-C). This trial is being conducted at 70 sites in the United States and includes 350 patients with IBS-C who will be treated with one of four doses of plecanatide (0.3, 1.0, 3.0, or 9.0 mg) or placebo, taken once daily over a period of 12 weeks. PAREXEL International is the Contract Research Organization for the trial. Patients must meet the Rome III criteria for IBS as demonstrated by a history of recurrent abdominal pain or discomfort covering at least three days/month in the last three months associated with two or more of: improvement with defecation, onset associated with a change in frequency of stool, and 3) onset associated with a change in form (appearance) of stool. Patients must also meet the criteria for the IBS-C subtype, which is further characterized by stool pattern such that = 25% of defecations are hard or lumpy stools and = 25% of defecations are loose or watery stools.  Full Article

Synergy Pharmaceuticals Inc Acquires FV-100 Shingles Drug From Bristol-Myers Squibb Co
Thursday, 23 Aug 2012 04:45pm EDT 

Synergy Pharmaceuticals Inc announced that it has signed an Asset Purchase Agreement with Bristol-Myers Squibb Co and has acquired the assets related to FV-100, an orally available nucleoside analogue, currently being developed for the treatment of shingles, a severe, painful skin rash caused by reactivation of the varicella zoster virus - the virus that causes chickenpox.  Full Article

Synergy Pharma constipation drug succeeds in trial

- Synergy Pharmaceuticals Inc said its constipation drug improved the frequency of complete spontaneous bowel movements in patients with a form of irritable bowel syndrome, reinforcing investor hopes that the data would boost chances of a buyout.

Search Stocks